Cochrane · systematic review · CD005583
Helicobacter pylori eradication for the prevention of gastric neoplasia
Ford, AC, Yuan, Y, Forman, D, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 20%Very low 0 · 0%Low 0 · 0%Moderate 4 · 80%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyH. pylori eradication therapy compared to control for the prevention of gastric neoplasia in healthy asymptomatic infected individuals
Population: healthy asymptomatic H. pylori‐infected individuals
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of gastric cancer ‐ modified ITT analysisHistological examination H. pylori eradication therapy vs control | RR 0.54 [0.4, 0.72] | 7 studies · 8323 participants | Moderate Downgraded: risk of bias, inconsistency, publication bias |
Death from gastric cancer ‐ modified ITT analysis H. pylori eradication therapy vs control | RR 0.61 [0.4, 0.92] | 4 studies · 6301 participants | Moderate Downgraded: risk of bias, inconsistency, publication bias |
Death from all causes ‐ modified ITT analysis H. pylori eradication therapy vs control | RR 0.97 [0.85, 1.12] | 5 studies · 7079 participants | Moderate Downgraded: risk of bias, inconsistency, publication bias |
Incidence of oesophageal squamous cell carcinoma ‐ modified ITT analysis H. pylori eradication therapy vs control | RR 1.22 [0.59, 2.54] | 2 studies · 3888 participants | Moderate |
Adverse events H. pylori eradication therapy vs control | no estimate extracted | 0 studies · 0 participants | Ungraded |
H. pylori eradication therapy compared to control for the prevention of gastric neoplasia in healthy asymptomatic infected individuals
Population: healthy asymptomatic H. pylori‐infected individuals
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of gastric cancer ‐ modified ITT analysis Histological examination H. pylori eradication therapy vs control | RR 0.66 [0.46, 0.95] | 6 studies · 6497 participants | Moderate Downgraded: risk of bias, inconsistency, publication bias |
Death from gastric cancer ‐ modified ITT analysis H. pylori eradication therapy vs control | RR 0.67 [0.4, 1.11] | 3 studies · 4475 participants | Moderate Downgraded: risk of bias, inconsistency, publication bias |
Death from all causes ‐ modified ITT analysis H. pylori eradication therapy vs control | RR 1.09 [0.86, 1.38] | 4 studies · 5253 participants | Moderate Downgraded: risk of bias, inconsistency, publication bias |
Incidence of oesophageal squamous cell carcinoma ‐ modified ITT analysis H. pylori eradication therapy vs control | RR 1.99 [0.18, 21.91] | 1 study · 1630 participants | Moderate Downgraded: imprecision |
Adverse events H. pylori eradication therapy vs control | no estimate extracted | 0 studies · 0 participants | Ungraded |